AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Addresses the significant threat of antimicrobial resistance.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

The New Hampshire Department of Health and Human Services (DHHS) said a person from Merrimack County has become the first ...

The diagnostics startup is developing a testing platform that uses digital imaging and signal processing for pathogen identification and susceptibility determination.

Researchers have succeeded in cultivating an ultra-small bacterial strain parasitizing archaea and classified it as new species and genus of Minisyncoccus archaeiphilus.